Richard R. Furman, MD

Articles

Dr. Furman on FDA-Approved BTK Inhibitors in B-Cell Malignancies

June 23rd 2020

Richard R. Furman, MD, discusses FDA-approved BTK inhibitors in B-cell malignancies.

Dr. Furman on the Safety of Acalabrutinib in Hematologic Malignancies

June 16th 2020

Richard R. Furman, MD, discusses the safety of acalabrutinib as a monotherapy in hematologic malignancies.

Dr. Furman on Differences Between BTK Inhibitors in B-Cell Malignancies

June 10th 2020

Richard R. Furman, MD, discusses differences among the different available BTK inhibitors for use in patients with B-cell malignancies.

Dr. Furman on Acalabrutinib Monotherapy in CLL

February 11th 2020

Richard R. Furman, MD, discusses acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Furman on Frontline Treatment Selection in CLL

November 22nd 2019

Richard R. Furman, MD, discusses the use of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Furman on Prognostic Markers in High-Risk CLL

November 7th 2019

Richard R. Furman, MD, discusses the role of prognostic markers in high-risk chronic lymphocytic leukemia.

CLL in the Era of Targeted Therapies

December 12th 2017

Over the past few years, remarkable advances have been achieved in the field of chronic lymphocytic leukemia by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival.

Dr. Furman on Exciting Available Agents for Patients With CLL

September 1st 2017

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the available agents that have shown promise for patients with chronic lymphocytic leukemia (CLL).

Dr. Furman on Considering Factors for Upfront Therapy in CLL

August 15th 2017

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses factors to consider when choosing upfront therapy for patients with chronic lymphocytic leukemia (CLL).

Dr. Furman on Second-Generation BTK Inhibitors in CLL

August 3rd 2017

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses second-generation BTK inhibitors, such as acalabrutinib and BGB-3111 in chronic lymphocytic leukemia (CLL).

Dr. Furman on Utility of Prognostic Markers in CLL

May 12th 2017

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the use of prognostic markers in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Furman on Avoiding Chemotherapy With Idelalisib

December 10th 2013

Richard R. Furman, MD, from the New York Weill Cornell Medical Center, discusses the ability to avoid the administration of chemotherapy when using novel agents, such as idelalisib, to treat patients with chronic lymphocytic leukemia.

Dr. Furman on Trials Examining Ibrutinib's Safety in CLL

January 18th 2013

Richard R. Furman, MD, from the Weill Cornell Medical Center, discusses the safety profile of the oral BTK inhibitor ibrutinib in both relapsed/refractory and treatment naive patients with chronic lymphocytic leukemia.